ENOVIS CORP (ENOV) Fundamental Analysis & Valuation

NYSE:ENOV • US1940141062

Current stock price

24.1 USD
+1.29 (+5.66%)
At close:
24.1 USD
0 (0%)
After Hours:

This ENOV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. ENOV Profitability Analysis

1.1 Basic Checks

  • In the past year ENOV was profitable.
  • In the past year ENOV had a positive cash flow from operations.
  • In the past 5 years ENOV reported 4 times negative net income.
  • ENOV had a positive operating cash flow in 4 of the past 5 years.
ENOV Yearly Net Income VS EBIT VS OCF VS FCFENOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500M -1B

1.2 Ratios

  • ENOV has a Return On Assets of -30.89%. This is comparable to the rest of the industry: ENOV outperforms 42.25% of its industry peers.
  • Looking at the Return On Equity, with a value of -79.51%, ENOV is doing worse than 60.43% of the companies in the same industry.
  • With a decent Return On Invested Capital value of 0.46%, ENOV is doing good in the industry, outperforming 66.84% of the companies in the same industry.
  • ENOV had an Average Return On Invested Capital over the past 3 years of 0.36%. This is significantly below the industry average of 9.12%.
  • The last Return On Invested Capital (0.46%) for ENOV is above the 3 year average (0.36%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -30.89%
ROE -79.51%
ROIC 0.46%
ROA(3y)-16.37%
ROA(5y)-9.72%
ROE(3y)-37.57%
ROE(5y)-22.31%
ROIC(3y)0.36%
ROIC(5y)N/A
ENOV Yearly ROA, ROE, ROICENOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60

1.3 Margins

  • With a decent Operating Margin value of 0.84%, ENOV is doing good in the industry, outperforming 66.84% of the companies in the same industry.
  • In the last couple of years the Operating Margin of ENOV has declined.
  • Looking at the Gross Margin, with a value of 58.16%, ENOV is in line with its industry, outperforming 58.82% of the companies in the same industry.
  • ENOV's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 0.84%
PM (TTM) N/A
GM 58.16%
OM growth 3YN/A
OM growth 5Y-34.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.43%
GM growth 5Y6.64%
ENOV Yearly Profit, Operating, Gross MarginsENOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ENOV Health Analysis

2.1 Basic Checks

  • ENOV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, ENOV has more shares outstanding
  • Compared to 5 years ago, ENOV has more shares outstanding
  • ENOV has a worse debt/assets ratio than last year.
ENOV Yearly Shares OutstandingENOV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
ENOV Yearly Total Debt VS Total AssetsENOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • ENOV has an Altman-Z score of 0.59. This is a bad value and indicates that ENOV is not financially healthy and even has some risk of bankruptcy.
  • ENOV has a Altman-Z score of 0.59. This is comparable to the rest of the industry: ENOV outperforms 47.59% of its industry peers.
  • The Debt to FCF ratio of ENOV is 65.11, which is on the high side as it means it would take ENOV, 65.11 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of ENOV (65.11) is better than 66.31% of its industry peers.
  • A Debt/Equity ratio of 0.85 indicates that ENOV is somewhat dependend on debt financing.
  • ENOV has a Debt to Equity ratio of 0.85. This is in the lower half of the industry: ENOV underperforms 75.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 65.11
Altman-Z 0.59
ROIC/WACC0.08
WACC5.42%
ENOV Yearly LT Debt VS Equity VS FCFENOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

  • ENOV has a Current Ratio of 2.02. This indicates that ENOV is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.02, ENOV is doing worse than 63.64% of the companies in the same industry.
  • A Quick Ratio of 1.04 indicates that ENOV should not have too much problems paying its short term obligations.
  • The Quick ratio of ENOV (1.04) is worse than 80.75% of its industry peers.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.04
ENOV Yearly Current Assets VS Current LiabilitesENOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ENOV Growth Analysis

3.1 Past

  • ENOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.61%, which is quite good.
  • ENOV shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -4.57% yearly.
  • Looking at the last year, ENOV shows a small growth in Revenue. The Revenue has grown by 6.66% in the last year.
  • Measured over the past years, ENOV shows a decrease in Revenue. The Revenue has been decreasing by -6.05% on average per year.
EPS 1Y (TTM)16.61%
EPS 3Y13.28%
EPS 5Y-4.57%
EPS Q2Q%-3.06%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y12.88%
Revenue growth 5Y-6.05%
Sales Q2Q%2.64%

3.2 Future

  • ENOV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.35% yearly.
  • Based on estimates for the next years, ENOV will show a small growth in Revenue. The Revenue will grow by 4.56% on average per year.
EPS Next Y11.93%
EPS Next 2Y11.63%
EPS Next 3Y11.35%
EPS Next 5YN/A
Revenue Next Year3.91%
Revenue Next 2Y4.61%
Revenue Next 3Y4.56%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ENOV Yearly Revenue VS EstimatesENOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B
ENOV Yearly EPS VS EstimatesENOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. ENOV Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 7.30 indicates a rather cheap valuation of ENOV.
  • 96.26% of the companies in the same industry are more expensive than ENOV, based on the Price/Earnings ratio.
  • ENOV is valuated cheaply when we compare the Price/Earnings ratio to 27.42, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 6.52, the valuation of ENOV can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, ENOV is valued cheaper than 97.86% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.24, ENOV is valued rather cheaply.
Industry RankSector Rank
PE 7.3
Fwd PE 6.52
ENOV Price Earnings VS Forward Price EarningsENOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ENOV indicates a rather cheap valuation: ENOV is cheaper than 94.12% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ENOV indicates a somewhat cheap valuation: ENOV is cheaper than 71.66% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 69.62
EV/EBITDA 8.21
ENOV Per share dataENOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • ENOV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.61
PEG (5Y)N/A
EPS Next 2Y11.63%
EPS Next 3Y11.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ENOV Dividend Analysis

5.1 Amount

  • No dividends for ENOV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENOV Fundamentals: All Metrics, Ratios and Statistics

ENOVIS CORP

NYSE:ENOV (4/24/2026, 8:04:00 PM)

After market: 24.1 0 (0%)

24.1

+1.29 (+5.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners118.02%
Inst Owner Change0.06%
Ins Owners1.72%
Ins Owner Change9.17%
Market Cap1.39B
Revenue(TTM)2.25B
Net Income(TTM)-1.18B
Analysts84.44
Price Target46.09 (91.24%)
Short Float %14.56%
Short Ratio8.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.33%
Min EPS beat(2)13.32%
Max EPS beat(2)13.35%
EPS beat(4)4
Avg EPS beat(4)10.31%
Min EPS beat(4)6.8%
Max EPS beat(4)13.35%
EPS beat(8)8
Avg EPS beat(8)8.3%
EPS beat(12)12
Avg EPS beat(12)8.63%
EPS beat(16)16
Avg EPS beat(16)9.44%
Revenue beat(2)0
Avg Revenue beat(2)-1.7%
Min Revenue beat(2)-3.32%
Max Revenue beat(2)-0.09%
Revenue beat(4)0
Avg Revenue beat(4)-1.4%
Min Revenue beat(4)-3.32%
Max Revenue beat(4)-0.09%
Revenue beat(8)1
Avg Revenue beat(8)-1.24%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)5
Avg Revenue beat(16)-1.09%
PT rev (1m)-0.6%
PT rev (3m)-0.6%
EPS NQ rev (1m)-0.02%
EPS NQ rev (3m)7.91%
EPS NY rev (1m)2.43%
EPS NY rev (3m)5.01%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)-1.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.71%
Valuation
Industry RankSector Rank
PE 7.3
Fwd PE 6.52
P/S 0.62
P/FCF 69.62
P/OCF 6.38
P/B 0.93
P/tB N/A
EV/EBITDA 8.21
EPS(TTM)3.3
EY13.69%
EPS(NY)3.69
Fwd EY15.33%
FCF(TTM)0.35
FCFY1.44%
OCF(TTM)3.78
OCFY15.67%
SpS39.07
BVpS25.89
TBVpS-8.09
PEG (NY)0.61
PEG (5Y)N/A
Graham Number43.8434 (81.92%)
Profitability
Industry RankSector Rank
ROA -30.89%
ROE -79.51%
ROCE 0.58%
ROIC 0.46%
ROICexc 0.46%
ROICexgc 1.19%
OM 0.84%
PM (TTM) N/A
GM 58.16%
FCFM 0.89%
ROA(3y)-16.37%
ROA(5y)-9.72%
ROE(3y)-37.57%
ROE(5y)-22.31%
ROIC(3y)0.36%
ROIC(5y)N/A
ROICexc(3y)0.36%
ROICexc(5y)N/A
ROICexgc(3y)1.26%
ROICexgc(5y)N/A
ROCE(3y)0.45%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-36.37%
ROICexc growth 3YN/A
ROICexc growth 5Y-29.16%
OM growth 3YN/A
OM growth 5Y-34.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.43%
GM growth 5Y6.64%
F-Score4
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 65.11
Debt/EBITDA 4.03
Cap/Depr 67.05%
Cap/Sales 8.78%
Interest Coverage 0.69
Cash Conversion 69.38%
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 1.04
Altman-Z 0.59
F-Score4
WACC5.42%
ROIC/WACC0.08
Cap/Depr(3y)62.27%
Cap/Depr(5y)54.89%
Cap/Sales(3y)8.17%
Cap/Sales(5y)7.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.61%
EPS 3Y13.28%
EPS 5Y-4.57%
EPS Q2Q%-3.06%
EPS Next Y11.93%
EPS Next 2Y11.63%
EPS Next 3Y11.35%
EPS Next 5YN/A
Revenue 1Y (TTM)6.66%
Revenue growth 3Y12.88%
Revenue growth 5Y-6.05%
Sales Q2Q%2.64%
Revenue Next Year3.91%
Revenue Next 2Y4.61%
Revenue Next 3Y4.56%
Revenue Next 5YN/A
EBIT growth 1Y53.77%
EBIT growth 3YN/A
EBIT growth 5Y-38.41%
EBIT Next Year53.84%
EBIT Next 3Y21.57%
EBIT Next 5YN/A
FCF growth 1Y129.63%
FCF growth 3YN/A
FCF growth 5Y-36.11%
OCF growth 1Y91.44%
OCF growth 3YN/A
OCF growth 5Y-6.37%

ENOVIS CORP / ENOV Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ENOVIS CORP (ENOV) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ENOV.


What is the valuation status of ENOVIS CORP (ENOV) stock?

ChartMill assigns a valuation rating of 8 / 10 to ENOVIS CORP (ENOV). This can be considered as Undervalued.


What is the profitability of ENOV stock?

ENOVIS CORP (ENOV) has a profitability rating of 4 / 10.


What are the PE and PB ratios of ENOVIS CORP (ENOV) stock?

The Price/Earnings (PE) ratio for ENOVIS CORP (ENOV) is 7.3 and the Price/Book (PB) ratio is 0.93.


Can you provide the financial health for ENOV stock?

The financial health rating of ENOVIS CORP (ENOV) is 3 / 10.